Guideline Recommendations for the Management of Allergic Conjunctivitis

First‑Line Pharmacologic Therapy for Mild Disease

• Initiate treatment with topical second‑generation H1‑antihistamines or dual‑action antihistamine/mast‑cell stabilizer agents; no predefined duration limit, continue as needed for symptom control. If response is inadequate, add a brief 1–2 week course of topical corticosteroids. 1
• Topical second‑generation H1‑antihistamines are more effective than over‑the‑counter antihistamine/vasoconstrictor combinations. 1, 2
• Dual‑action agents may be used for either acute or chronic allergic conjunctivitis without a specified duration limit. 1, 2
• Chronic use of vasoconstrictor‑containing drops should be avoided because rebound vasodilation occurs after discontinuation. 1, 2

Management of Recurrent or Persistent Disease

• Add mast‑cell stabilizer therapy for frequently recurrent or persistent symptoms. 1, 2
• Newer agents that combine antihistamine and mast‑cell stabilizing properties are suitable for long‑term use in chronic disease. 1, 3
• No specific duration limit is provided for chronic mast‑cell stabilizer therapy. 1

Second‑Line Therapy for Inadequate Response

• Use low‑risk topical corticosteroids for a brief 1–2 week course when symptoms are not adequately controlled with antihistamines/dual‑action agents. 1, 3, 2

Treatment of Severe or Refractory Cases

• Topical cyclosporine 0.05 % should be administered at least four times daily for severe allergic conjunctivitis and is effective in preventing seasonal recurrences. 1, 3
• Topical cyclosporine 0.1 % is FDA‑approved for vernal keratoconjunctivitis in both children and adults. 1, 3
• Topical tacrolimus may be considered for severe cases that are refractory to other treatments. 1, 3

Monitoring Requirements When Using Corticosteroids

• Obtain baseline and periodic intra‑ocular pressure (IOP) measurements for any patient receiving corticosteroids in chronic or recurrent conjunctivitis. 1, 3, 2
• Perform periodic pupillary dilation to assess for cataract formation during corticosteroid therapy. 1, 3
• Monitoring is required for any steroid use extending beyond the brief 1–2 week course. 1

Cautions and Adjunctive Measures

• Oral antihistamines can induce or worsen dry‑eye syndrome and impair the tear film; use them cautiously or avoid them. 1, 3, 2
• If oral antihistamines are used, prescribe preservative‑free artificial tears to mitigate tear‑film deficiency. 1, 3
• Counsel patients to avoid eye rubbing, as allergic conjunctivitis and atopic disease are linked to keratoconus and increased risk of corneal ectasia progression. 1, 3, 2
• Cold compresses and refrigerated artificial tears provide symptomatic relief and help dilute allergens and inflammatory mediators on the ocular surface. 1, 2
• Implement allergen‑avoidance strategies such as wearing sunglasses, using hypoallergenic bedding, employing eyelid cleansers, washing clothes frequently, and bathing before bedtime. 1, 2

Duration Summary for Therapeutic Classes

• Antihistamines and dual‑action agents: no specified duration limit; continue as needed for symptom control. 1, 2
• Mast‑cell stabilizers: no specified duration limit for chronic/recurrent disease. 1
• Topical corticosteroids: limit to 1–2 weeks for acute exacerbations. 1, 3, 2
• Topical immunomodulators (cyclosporine or tacrolimus): can be used long‑term for severe cases to reduce dependence on steroids. 1, 3

Evidence‑Based Management of Ocular Pruritus (Eye Itching)

First‑Line Pharmacologic Considerations

• Chronic use of vasoconstrictor‑containing eye drops should be avoided because discontinuation commonly leads to rebound vasodilation and worsening ocular redness in patients with allergic eye disease. 4

Adjunctive Non‑Pharmacologic Measures

• Applying cold compresses together with refrigerated artificial tears provides immediate symptomatic relief and helps dilute allergens and inflammatory mediators on the ocular surface of individuals with ocular itching. 4
• Implementing allergen‑avoidance strategies—such as wearing sunglasses, using hypoallergenic bedding, cleansing eyelid margins, washing clothing frequently, and showering before bedtime—reduces exposure to ocular allergens and supports symptom control. 4

Management of Persistent or Recurrent Symptoms

• Adding a mast‑cell stabilizer to the regimen is recommended for patients with frequently recurrent or persistent ocular pruritus that does not respond adequately to antihistamine therapy alone. 4
• If symptoms remain inadequately controlled after antihistamine ± mast‑cell stabilizer therapy, a brief (1–2 week) course of low‑risk topical corticosteroids can be introduced to achieve additional symptom relief. 4

Severe or Refractory Cases

• Topical tacrolimus may be considered for severe allergic conjunctivitis that is refractory to other treatments, offering an alternative immunomodulatory option. 4

Cautions Regarding Systemic and Steroid Therapy

• Oral antihistamines should be used cautiously because they can induce or exacerbate dry‑eye syndrome and impair the protective tear‑film barrier in patients with ocular itching. 4
• When oral antihistamines are necessary, concomitant prescription of preservative‑free artificial tears is advised to mitigate tear‑film deficiency. 4
• Indiscriminate use of topical corticosteroids can prolong adenoviral infections and worsen herpes simplex virus infections, therefore steroid therapy should be limited to appropriate indications and durations. 4

Management of Shield Ulcers in Vernal Keratoconjunctivitis

Initial Medical Management (Grade 1 Ulcers without Plaque)

• Aggressive topical corticosteroid therapy (e.g., prednisolone 1% or dexamethasone 1%) four times daily is recommended to control severe inflammation in shield ulcers. 5, 6
• Topical cyclosporine 0.05% should be started at least four times daily (up to eight times daily for severe disease) to provide immunomodulation. 5, 6
• Cyclosporine 0.1% is FDA‑approved for VKC and represents the highest regulatory standard for this indication. 5, 6, 7

Escalation for Non‑Response or Higher‑Grade Ulcers (1–2 Weeks)

• Supratarsal corticosteroid injection is advised for sight‑threatening cases that do not respond to intensive topical therapy. 5, 6, 7

Post‑Treatment Management

• Long‑term continuation of topical immunomodulators (cyclosporine or tacrolimus) is recommended to prevent seasonal recurrences and to reduce dependence on steroids. 5, 6
• After re‑epithelialization, corticosteroids should be tapered to minimize the risk of steroid‑induced glaucoma and cataract. 5, 6, 7
• Baseline and periodic intra‑ocular pressure measurements, together with pupillary dilation to assess for cataract, are mandatory when patients are receiving corticosteroids. 5, 6, 7

Safety Considerations and Common Pitfalls

• Prolonged corticosteroid monotherapy increases the risk of glaucoma, cataract, and fails to address the underlying T‑cell‑mediated inflammation; therefore, combination therapy with immunomodulators is preferred. 5, 6, 7
• Patients should be counseled to avoid eye rubbing because VKC is linked to keratoconus progression; controlling inflammation and minimizing mechanical trauma are essential. 5, 6, 7, 8
• Calcineurin inhibitors (cyclosporine or tacrolimus) may increase susceptibility to herpes simplex keratitis; clinicians should monitor for viral reactivation. 5, 6, 9